Advertisement

Your search for hematologic malignancies matches 207 pages

Showing 201 - 207


hematologic malignancies
leukemia

High Rate of Durable Remissions with BTK Inhibitor Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia

Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase (BTK) is an essential component of B-cell receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of...

hematologic malignancies

Critically Ill Patients with Hematologic Malignancies Admitted to ICU Have Good Survival, Disease Control, and Quality of Life

A large prospective multicenter cohort study in France and Belgium, reported by the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique, has shown that critically ill patients with hematologic malignancies admitted to the intensive care unit (ICU) have good survival,...

hematologic malignancies

FDA Grants Orphan Drug Status for Novel Targeted Therapy for the Treatment of Rare Hematologic Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Stemline Therapeutics' SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive hematologic malignancy for which there is no effective treatment. SL-401 also has Orphan Drug...

hematologic malignancies

New Research Shows Significant Improvement in Overall Survival Outcomes for Patients Receiving Blood Stem Cell Transplants

Survival rates have increased significantly among patients who received blood stem cell transplants from both related and unrelated donors, according to a study published in the Journal of Clinical Oncology. The study authors attribute the increase to several factors, including advances in HLA...

hematologic malignancies
leukemia
lymphoma

St. Jude Children's Research Hospital Announces Issuance of U.S. Patent for Genetically Modified Human Immune Cells for Cancer Therapy

The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for its invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults. "This...

hematologic malignancies
leukemia
survivorship

Risk of Leukemia After Cancer Chemotherapy Persists

While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online in Blood, the Journal of the American Society of...

hematologic malignancies

Ezatiostat Gets Orphan Designation for Treatment of Myelodysplastic Syndrome

Telik, Inc, announced that its product candidate, ezatiostat hydrochloride (Telintra), has been granted orphan drug designation by the FDA for the treatment of myelodysplastic syndrome (MDS). Ezatiostat is an investigational agent in development for the treatment of MDS and idiopathic chronic...

Advertisement



Advertisement